Zobrazeno 1 - 10
of 745
pro vyhledávání: '"David J, Cole"'
Autor:
Shikhar Mehrotra, Carolyn D. Britten, Steve Chin, Elizabeth Garrett-Mayer, Colleen A. Cloud, Mingli Li, Gina Scurti, Mohamed L. Salem, Michelle H. Nelson, Melanie B. Thomas, Chrystal M. Paulos, Andres M. Salazar, Michael I. Nishimura, Mark P. Rubinstein, Zihai Li, David J. Cole
Publikováno v:
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-13 (2017)
Abstract Background Dendritic cells (DCs) enhance the quality of anti-tumor immune response in patients with cancer. Thus, we posit that DC-based immunotherapy, in conjunction with toll-like receptor (TLR)-3 agonist poly-ICLC, is a promising approach
Externí odkaz:
https://doaj.org/article/24af04bf4a4248ecafa4d737c8c57263
Autor:
Mark P. Rubinstein, David J. Cole, Shikhar Mehrotra, Elizabeth Garrett-Mayer, Kevin F. Staveley-O'Carroll, Guangfu Li, Stuart C. Gilreath, Bennett R. May, Brian P. Riesenberg, C. Bryce Johnson
Figure S1. Blockade of IL-7 but not IL-2 reduces engraftment of IL-12 conditioned (Tc1) CD8+ T cells in lymphodepleted mice. Figure S2. Blockade of cytokine signaling does not reduce the functionality of donor CD8+ T cells. Figure S3. Activated CD8+
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55fc0b447e98036326de3f5be93fe5d5
https://doi.org/10.1158/2326-6066.22537865.v1
https://doi.org/10.1158/2326-6066.22537865.v1
Autor:
Ananda W. Goldrath, Jack D. Bui, David J. Cole, Megan K. Baker, David H. Craig, J. Adam Best, Emilie T. Gross, Mark P. Rubinstein, Andrew L. Doedens
PyMT tumor versus spleen fold change, acute infection day 6 versus spleen fold change.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46a8ba9b195fb816397409fa0c6e1b70
https://doi.org/10.1158/2326-6066.22537717
https://doi.org/10.1158/2326-6066.22537717
Autor:
Ananda W. Goldrath, Jack D. Bui, David J. Cole, Megan K. Baker, David H. Craig, J. Adam Best, Emilie T. Gross, Mark P. Rubinstein, Andrew L. Doedens
Selected phosphatases up-regulated in PyMT tumor CD8+ T cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::820700add58d7f6b53aa9dfc7f45fb9e
https://doi.org/10.1158/2326-6066.22537705.v1
https://doi.org/10.1158/2326-6066.22537705.v1
Autor:
Ananda W. Goldrath, Jack D. Bui, David J. Cole, Megan K. Baker, David H. Craig, J. Adam Best, Emilie T. Gross, Mark P. Rubinstein, Andrew L. Doedens
PyMT tumor CD8+ versus day 5 effector OT-I gene expression and fold change.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65f83392c9f161140201446feeb0b064
https://doi.org/10.1158/2326-6066.22537723
https://doi.org/10.1158/2326-6066.22537723
Autor:
Mark P. Rubinstein, David J. Cole, Shikhar Mehrotra, Elizabeth Garrett-Mayer, Kevin F. Staveley-O'Carroll, Guangfu Li, Stuart C. Gilreath, Bennett R. May, Brian P. Riesenberg, C. Bryce Johnson
Adoptive cellular therapy, in which activated tumor-reactive T cells are transferred into lymphodepleted recipients, is a promising cancer treatment option. Activation of T cells decreases IL7 responsiveness; therefore, IL15 is generally considered t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2438f3e0154a753ac008da979de2c4d
https://doi.org/10.1158/2326-6066.c.6548579.v1
https://doi.org/10.1158/2326-6066.c.6548579.v1
Autor:
Ananda W. Goldrath, Jack D. Bui, David J. Cole, Megan K. Baker, David H. Craig, J. Adam Best, Emilie T. Gross, Mark P. Rubinstein, Andrew L. Doedens
Despite clinical potential and recent advances, durable immunotherapeutic ablation of solid tumors is not routinely achieved. IL15 expands natural killer cell (NK), natural killer T cell (NKT) and CD8+ T-cell numbers and engages the cytotoxic program
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b950fdf94633ed97d2bceaa098bc4d01
https://doi.org/10.1158/2326-6066.c.6548530.v1
https://doi.org/10.1158/2326-6066.c.6548530.v1
Autor:
Ananda W. Goldrath, Jack D. Bui, David J. Cole, Megan K. Baker, David H. Craig, J. Adam Best, Emilie T. Gross, Mark P. Rubinstein, Andrew L. Doedens
PyMT tumor CD8+ versus day 1 effector OT-I gene expression and fold change.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::643f73d85a2f51848e9e98995b1eb8a0
https://doi.org/10.1158/2326-6066.22537726.v1
https://doi.org/10.1158/2326-6066.22537726.v1
Autor:
Ananda W. Goldrath, Jack D. Bui, David J. Cole, Megan K. Baker, David H. Craig, J. Adam Best, Emilie T. Gross, Mark P. Rubinstein, Andrew L. Doedens
Supplemental Figure 1: Five day IL-15cx treatment results in splenic CD8+ T cell activation and up-regulation of cytotoxic molecule expression in PyMT tumor-bearing mice. Supplemental Figure 2: PyMT tumor single-cell suspensions induce IL-2 / IL-15 r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8a78216c1551b9f8f80d3da972c28c6
https://doi.org/10.1158/2326-6066.22537732.v1
https://doi.org/10.1158/2326-6066.22537732.v1
Autor:
Ananda W. Goldrath, Jack D. Bui, David J. Cole, Megan K. Baker, David H. Craig, J. Adam Best, Emilie T. Gross, Mark P. Rubinstein, Andrew L. Doedens
Transcripts up-regulated {greater than or equal to}2-fold in PyMT tumor versus splenic CD8+ T cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3111e97a4fd65e74facf081533861fb8
https://doi.org/10.1158/2326-6066.22537714
https://doi.org/10.1158/2326-6066.22537714